temporal

We are pleased to announce that the findings from our recent acromegaly and NETs global survey have been published in Advances in Therapy, in the paper titled:

 

Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours

 

The scientific committee surveyed patients, HCPs and non-HCP caregivers to assess current opinion surrounding SRL device attributes associated with the most favourable injection experience for people living with acromegaly and neuroendocrine tumours (NETs).

The findings identify the key features of injection devices for SRL therapy and underscore the importance of involving patients in treatment decisions.

Read the publication, download the survey overview and get the key clinical takeaways below.

 

 

 

Clinical Takeaways

 

  • Attributes that significantly impact the treatment experience for both patients and caregivers include ease and confidence of device use, device safety with a focus on minimising contamination risks and less burdensome injections

  • The survey underscores the need to boost confidence in administering SRL injections for non-HCP caregivers and self-injecting patients. Achieving this involves device-specific training, patient education, instructional videos, online resources, and continued support from HCPs

  • Patient and caregiver opinions play a crucial role in advancing device design, enabling shared decision-making, and selecting suitable injection devices tailored to individual therapeutic requirements

Scientific Committee

Dr Jens Otto Lunde Jørgensen, Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark

Prof. Wouter de Herder, Department of Internal Medicine-Endocrinology, Erasmus University Medical Centre, Rotterdam, Netherlands

Mrs Wendy Martin, King's College Hospital, London, UK

Ms Teodora Kolarova, International Neuroendocrine Cancer Alliance (INCA), Boston, MA, USA

Ms Muriël Marks, World Alliance of Pituitary Organizations (WAPO), Amsterdam, Netherlands

Ms Cecilia Follin, Lund University Cancer Centre, Lund, Sweden

Ms Wanda Geilvoet, Department of Internal Medicine-Endocrinology, Erasmus University Medical Centre, Rotterdam, Netherlands

Prof. Shlomo Melmed, Pituitary Center, Dept of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Programme summary
Share this programme
Educational programme supported by an independent medical education grant from Ipsen
Endorsement
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
Conference update

Episode

1

of 4

episode
Oncology 
ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

Experts
Prof. Mark Socinski
  • clock 4 MIN
  • calendar Jun 2024

Conference update

Episode

2

of 4

episode
Oncology 
ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

Experts
Prof. Shaheenah Dawood
  • clock 3 MIN
  • calendar Jun 2024

Conference update

Episode

3

of 4

episode
Oncology 
ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?

Experts
Prof. Dr Peter R. Galle
  • clock 1 MIN
  • calendar Jun 2024